Latest Intellectual Property News

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Alexium International Group Limited has announced a pro rata non-renounceable rights issue to raise approximately AUD 6.77 million, primarily to repay shareholder loans and finance the acquisition of Microtek Laboratories' microencapsulation business.

Alexium International has acquired Microtek Laboratories’ microencapsulation and phase-change material business, backed by a $6.8 million entitlement offer to strengthen its manufacturing and innovation capabilities in the US.

Electro Optic Systems has inked a conditional US$80 million contract to supply a 100kW high energy laser weapon to a South Korean customer, marking its second major export order in this advanced defence technology.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

International Graphite Limited projects robust financial returns from its new expandable graphite facility joint venture in Germany, targeting production start in mid-2027 with rapid payback and low capital costs.

ChemX Materials Limited has emerged from voluntary administration following a Deed of Company Arrangement, while securing a significant Japanese patent for its HiPurA® High Purity Alumina process.

EPX Limited has submitted a proposal to acquire WattWatchers Pty Limited through a Deed of Company Arrangement, pending creditor approval. The move aims to integrate WattWatchers’ real-time energy monitoring solutions with EPX’s advanced building performance platform.